Pesticides manufacturer FMC killed investors’ hopes when it missed its revenue guidance because of sales downturn. Furious investors plucked their shares out of FMC, causing the Company’s stock price to fall 33% overnight. Some investors have filed a class-action against FMC to recover their lost “green.”

In late 2023, FMC announced its annual outlook, projecting 3% revenue growth in the coming year. A few months later, FMC also announced “Project Focus,” an effort to cut costs in response to a downturn in Latin America and other areas. Still, FMC executives remained confident in the revenue growth projection.

Investors were shocked when, in February 2025, FMC executives revealed revenue was down 5%. Executives blamed the “unprecedented downturn” on weak demand in Latin America and other areas.

Stunned investors quickly dumped their FMC shares, causing the stock price to tumble. Some investors are now joining the class action.

When ICON revealed a “revenue shortfall” of $100 million and slashed financial projections, investors quickly dumped their shares.  ICON’s stock price plunged 20%, prompting some investors to file a class-action lawsuit to recover their losses. 

ICON is a research organization that assists biotech companies complete clinical trials.  When the pharmaceutical industry got hit with rising costs and high interest rates, those companies dumped ICON to reduce costs.  But ICON executives told investors it was benefitting from these market shifts and said business had “never been better.”   

Investors learned the truth in October 2024 when ICON issued a shocking financial report.  It revealed a $100 million “revenue shortfall” and slashed its annual revenue guidance by $220 million.  Analyst research revealed ICON executives knew about those problems for months beforehand but hid the truth from investors. 

Shocked investors quickly sold off their ICON stock.  Some of those investors are now joining the class-action lawsuit.  

Neumora shocked investors and analysts when it announced its antidepressant navacaprant flopped in clinical trials.  Shocked investors quickly sold off their shares, and Neumora’s stock price tumbled.  Some investors filed a class-action against the Company to recover their losses.  

Neurmora conducted an IPO in September 2023.  At that time, the Company was conducting Phase 2 trials on navacaprant, a investigatory anti-depressant drug.  The lawsuit says the Phase 2 trials had major issues, such as being too small and being poorly designed to control for gender.    

In January 2025, Neumora revealed navacaprant failed the Phase 3 trial.  Analysts were shocked and called the failure a “worst case scenario.”  Analysts noted the severe design issues and said the study failure might have been prevented from the start, if the study had been designed properly.   

Since the IPO, Neumora’s stock price has fallen 88.7%.  Some Neumora investors are now joining the class action lawsuit.   

ModivCare made investors sick when it revealed its cash flow was on life support and the Company had liquidity problems.  After learning this news, investors rapidly dumped their shares and ModivCare’s stock price dropped 10% overnight.  Some of those investors have filed a class-action lawsuit against the Company. 

ModivCare provides medical services including medical transport services.  In 2022, the Company’s CEO revealed ModivCare was renegotiating many of its transport contracts.  But, he reassured investors this was going to be “beneficial.”   He later raised the Company’s revenue guidance when discussing these contracts. 

 But behind the scenes, ModivCare executives knew things were bad.  The Company repeatedly announced negative cash flow and had racked up debt.  By September 2024, the Company announced it was having major liquidity problems.   A couple days later, the ModivCare slashed its guidance.   

 Stunned investors quickly sold off their shares.  Some of those investors are now joining the class-action.   

Investors in GSK got heartburn when they discovered the pharmaceutical giant might be on the hook for billions in a lawsuit about its drug Zantac.  Stunned investors quickly dumped their GSK shares, causing GSK’s price to drop 13% in less than a week.  Some of those investors have filed a class-action to recover their losses.

GSK manufactured Zantac, a best-selling heartburn drug.  But, since at least 1983, GSK knew Zantac could cause cancer, but swept that evidence under the rug.  GSK routinely denied Zantac caused cancer and claimed the drug was safe.

When Zantac users who developed cancer used GSK, the Company denied the allegations and said the science didn’t back it up.  But, in 2022, Credit Suisse estimated GSK was probably liable for up to ten billion dollars.

Investors rapidly sold their shares on this news.  Some of those investors are now joining the lawsuit. 

When Integral Ad Science slashed its ad prices, it ended up slashing its bottom line instead. Now, angry investors have filed a class-action lawsuit against the Company to recover their losses.

Throughout 2023, Integral’s CEO boasted about scoring new contracts with major clients. She said the reason for the Company’s success was customer service and great technology. But, what she didn’t tell investors was that Integral was offering bargain prices it couldn’t sustain.

Investors learned the truth in February 2024 when the Company issued an awful earnings report. Integral revealed it was offering massive discounts to clients to score contracts. Analysts said they were shocked by the revelation.

Stunned quickly dumped their shares, causing Integral’s stock price to tumble 41% overnight. Some of those investors are now joining the lawsuit.

After federal investigators made stunning allegations against pharmacy giant Walgreens Boots Alliance ("Walgreens"), Walgreens’ stock plunged 12% in just a day.  Now, some furious investors have filed a class-action lawsuit against the Company.

For years, Walgreens reported making billions on prescription drug sales.  The Company said it followed controlled substance laws, especially related to opioids.  But, the lawsuit says that was a lie.

In January 2025, the U.S. Department of Justice ("DOJ") filed charges against Walgreens.  The DOJ alleges Walgreens told pharmacists to purposefully violate the Controlled Substances Act.  This alleged conduct helped the Company drive up revenue on the back of wrongful opioid sales.  Some of those prescriptions fraudulently billed Medicare and Medicaid, according to the DOJ.

After learning of the DOJ allegations, investors rapidly dumped their shares.  Some of those investors are now joining the class-action lawsuit.

When Telus International shifted from call centers to AI, its finances took a huge hit. Telus shareholders are now suing the Company to recover their losses.

Tech company Telus International typically provided call center solutions to businesses. But, in 2020 it shifted toward AI, despite the call centers’ proven success.

Throughout 2023, Telus’ CEO boasted about the AI market’s growth potential and said the Company was doing extremely well in AI. At the same time, though, the Company experienced losses which Telus blamed on “macroeconomic pressures.” The Complaint says Telus executives knew that wasn’t true.

Investors learned the truth in August 2024 when the Company announced staggering losses, including a 15% decline in revenue. The CEO admitted these losses were due to the move to AI “cannibalizing” Telus’ traditional call center revenue.

Furious investors quickly dumped their Telus shares, sending the Company’s stock tumbling 36% overnight. Now, some of those investors are joining the lawsuit.

Investors discovered there was something rotten at Grocery Outlet after the discount grocer released a sour finance report.   Once investors got a sniff of the truth – that a tech roll-out gone wrong was costing the Company millions – shareholders quickly tossed out their shares, sending Grocery Outlet’s stock price plummeting 19%.  Now, some of those shareholders have filed a class-action lawsuit to recover their losses. 

In November 2023, Grocery Outlet executives told investors the Company was undergoing a “systems transitions” would hurt financial results for the remainder of the year.  But, Company executives assured investors the disruption would be done by the end of 2023.   

Investors first got a whiff that something was wrong when, in February 2024, the Company announced the transition as taking “longer than anticipated,” so first quarter financial results had also gone bad. 

But investors lost their patience in May 2024 when the Company released a dire financial report in which it admitted the transition continued to hurt finances.  Analysts were stunned and investors quickly sold off their shares. 

Now, some of those investors are joining the lawsuit.   

Advertising firm Cardlytics didn’t seal the deal with investors after it announced revenue and billings were way down.  Angry investors quickly dumped Carlytics stock, causing the Company’s share price to plunge a staggering 57% in one day.  Some of those shareholders are now suing the Company to recover their losses. 

 Cardlytics operates an advertising platform.  It partners with companies to offer consumers discounts and incentives, which are paid out of Cardlytics’ pocket.  In March 2024, the Company issued a glowing financial report and said it was on the path to major revenue growth throughout the year.   

 But that wasn’t the case.   

 The Company’s incentive program cost way too much.  In August 2024 the Company revealed revenues were down 9%t because incentive payments were out of control.  The Company slashed then slashed its financial projections. 

 Stunned investors quickly sold off their shares.  Some of those investors are now joining the lawsuit.    

Pharmaceutical giant Novo Nordisk made investors sick when it revealed a weight loss study went wrong.  Angry investors turned the scales against Novo and tossed out their shares, sending Novo’s share price tumbling over 17% in just one day.  Now, some investors have filed class-action against the Company to recover their losses.  

Novo conducted the REDEFINE study on obesity treatment.  The study looked at Novo’s new drug, CagriSema, in combination with Wegovy. 

The study design said participants would receive a set dose of CagriSema and Wegovy.   

For nearly two years, Novo’s CEO repeatedly said participants would lose at least 25% of their body weight.  But, the lawsuit says he wasn’t being honest. 

In December 2024, Novo published the study results.  Investors were stunned to find out Novo let participants vary their dosage – a big change from the study protocol.  And, participants lost an average of 22.7%t of their body weight.  Analysts called that a huge disappointment and a major difference from the promised 25% weight reduction. 

Stunned investors quickly dumped their shares after learning of the study results. Now, some investors are joining the lawsuit.  

When Essa Pharma announced its key drug, masofaniten, was complete dud, investors pulled the plug on the stock. The sell-off caused Essa’s stock price to plummet a staggering 73% overnight. Shocked shareholders are now taking legal action against the Company.

Essa was investigating masofaniten as a potential prostate cancer treatment. The study combined masofanien with another proven prostate cancer treatment to see if the combo worked even more effectively. In throughout most of 2024, the Company bragged about its Phase 1 study, which the Company claimed was a total success. Essa moved on to a Phase 2 trial about the drug combo.

So investors were stunned in October 2024 when the Company suddenly announced it was not only halting the Phase 2 study, but all studies about masofaniten. The announcement revealed the combination of masofaniten and the proven treatment was actually less effective than the proven treatment alone – meaning masofaniten was a total failure.

The announcement shocked investors and prompted a rapid sell-off of ESSA shares. Now, some of the angry investors are joining the lawsuit.

Investors’ hopes went up in smoke after Innovative Industrial Properties revealed one of its major tenants defaulted on its leases.  The news caused the Company’s stock price to tumble twenty-two percent overnight, prompting some investors to take legal action.

Innovative Industrial Properties leases real estate to government-licensed cannabis companies.   Throughout 2024, Innovative boasted it was going to see a lot of “green” from new leases, especially from its top client PharmaCann.   For three consecutive quarters, the Company's executives boasted about the Company's strong earnings and in particular stated it saw "strong value" in PharmaCann after penning four new leases with the company. 

But, the lawsuit alleges Innovative's executives knew that things were ready to go up in smoke.

Investors were stunned in December 2024 when Innovative revealed PharmaCann defaulted on all eleven of its leases, costing Innovative millions of dollars.

Shocked investors quickly sold their shares, plummeting Innovative’s stock price.

Now, some of those investors signing up for the lawsuit.

State and federal authorities made explosive AML and fraud allegations against Block, the owner of Cash App.  Block paid out $255 million dollars in fines, shocking investors.  Some of those stunned investors are now suing the Company.

Cash App – a popular banking app – was the target of a shocking short-seller investigation in February 2023.  The report alleged Cash App failed to follow anti-money laundering ("AML") laws and turned its eye toward illegal activities done on the platform.  The report further alleged Block's executives knew of these problems but failed to do anything about it.

Forty-eight state attorneys general teamed up after the report to investigate the allegations.  In January 2025, they announced a settlement with Cash App, requiring it to pay a $80 million penalty.

But that wasn’t the end of Cash App’s problems.  The next day, the federal Consumer Financial Protection Bureau ("CFPB") slapped a staggering $180 million penalty on Cash App for putting users at risk of fraud and failing to adequately protect users' information.

Since the shortseller report was published, Block's stock has suffered repeated losses.  Investors are now suing the Company to recover their investment.

A Department of Justice investigation into pharmaceutical manufacturer Regeneron left investors wide-eyed. The stunning allegations caused investors to rapidly sell off their shares and Regeneron’s stock price plunged over nine percent. Some of those investors are now joining a class-action lawsuit against the Company.

Regeneron’s leading products are Eylea and Eylea HD, drugs which treat macular degeneration. In the Company’s February 2024 quarterly financial report, Regeneron reported making $1.4 billion on the Eylea brand. Some of this money came from billing Medicaid and Medicare for Eylea prescriptions.

But, the lawsuit alleges Regeneron’s executives knew the Eylea sales figures were based on fraudulent Medicaid and Medicare billing practices.

In April 2024, the U.S Department of Justice filed a case against the Company alleging Regeneron regularly overbilled the Government for Regeneron prescriptions.

In October, investors learned how much overbilling propped up Regeneron’s bottom line. Quarterly sales for Eylea were $30 million below expectations, due to what the Company called a “lower net selling price.”

Investors quickly dumped their shares after learning this news. Some of those investors are now joining the lawsuit.

Micron Technology’s financial projections short-circuited after it slashed financial projections for 2025.  Investors were stunned, since Micron previously guided to a profitable year.    Shareholders rapidly sold off their stock, causing Micron’s stock price plunging 16%.  Some of those shareholders are taking legal action to recover their losses.

The microchip and computer memory industry suffered weak demand through 2022 and 2023.  But throughout 2024, Micron claimed it made a comeback, especially in its NAND sector.  The Company said it was in a position to “deliver a substantial revenue record” in 2025.

But in December 2024, the Company shocked analysts and investors by claiming its NAND sector suffered a major slowdown.  It also slashed its 2025 guidance.  Analysts responded negatively, cutting their targets for Micron and downgrading their ratings of the stock.  

Investors quickly dumped their shares, causing Micron’s stock to plummet.  Some of those investors are now joining the lawsuit.

Investors’ hopes went dim after solar power company Nextracker revealed its business was slowing down.  This slowdown stunned investors because Nextracker executives had been adamant the business was doing great.  Shocked shareholders dumped their stock, sending share prices tumbling 15%.  Now, some of those investors are taking legal action against the Company.   

Throughout 2024, the solar power industry experienced delays and slowdowns for various reasons. Nonetheless, Nextracker was adamant its business wasn’t slowing down and consistently reported record revenues and profits. The lawsuit alleges Nexttracker executives knew those claims weren’t true. 

 In October 2024, the Company shocked investors and analysts when it admitted it was experiencing the same slowdowns as the rest of the industry.  After Nextracker reported decreased revenues and profits, shareholders raced for the exit.  The news sent Nextracker’s stock price down 15%. 

Some of those angry investors are now joining the lawsuit. 

When BioAge labs announced it was pulling the plug on clinical trials of one of its drugs, investors then pulled the plug on BioAge Labs.  Shareholders quickly dumped their shares and BioAge’s stock price plunged 25% overnight.  Some of those investors are now taking legal action against the Company.

BioAge was investigating a potential obesity treatment called azelaprag.  It had completed Phase 1 trials.  The Phase 2 trial, called STRIDE, was set to complete in late 2025.  BioAge went public in September 2024.  In its IPO papers, BioAge touted azelaprag, the success of the Phase 1 trials, and the ongoing STRIDE trials. 

So investors were shocked in December 2024 when BioAge suddenly halted the STRIDE trial.  The Company revealed some STRIDE participants were showed signs of liver toxicity.  Analysts expressed surprise at the news, noting it is unusual that that liver toxicity had never appeared across any of the eight Phase 1 trials or other investigations BioAge conducted on the drug.

Investors rapidly sold off their shares and BioAge’s stock price plummeted.  Now, some of those investors are joining the lawsuit.

Investors in Revance were stunned after a merger deal took a bad turn, which analysts said caused Revance "reputational damage." The news sent the stock into a free fall, losing 20% in one day.  Furious investors are taking legal action to recover their losses.

In 2020, Biotech company Revance penned a distribution agreement with Teoxane.  The agreement required Revance maintain set purchasing and distribution levels for some of Teoxane’s products. 

In August 2024, Revance announced Crown Labs sought to buy out Revance for $6.66 per share.  Revance’s board agreed to the deal. But in September 2024, Revance announced it received a notice from Teoxane alleging Revance breached the distribution agreement.  Considering that allegation, Crown and Revance put their deal on hold.

Then, in December 2024, Revance announced it finalized the deal with Crown – but Crown slashed its offer by over 50%, to only $3.10 per share. Analysts were stunned by the move and called it a “significant devaluation.”

Investors quickly dumped their stock, causing Revance’s stock price to plunge.  Now, some of those investors are joining the lawsuit.

Investors in Caribou Biosciences were shocked after an analyst report revealed the pharmaceutical firm’s new drug posed safety concerns.  When investors realized they’d been sold snake water, they quickly sold their shares, sending Caribou’s stock price tumbling 25%.  Now, some of those investors are taking legal action to recover their losses.

Caribou Biosciences was researching a new drug called CB 010, which might treat Hodgkin Lymphoma.  In its financial reports, Caribou repeatedly claimed CB 010 showed promising results.  Company executives also claimed Caribou was in great financial shape, with enough cash to last until at least 2026.  But, Caribou executives knew better.

Investors learned the truth in June 2024 when Evercore published a report questioning CB-010’s effectiveness and calling the drug a “safety risk.”  In July 2024, Caribou blindsided investors when it admitted it was running out of cash and had to seriously curtail research activities.

Shocked investors quickly dumped their shares.  Some of those investors are now suing the company.  

Transocean’s stock price sank after it sold two of its rigs for a $630 million loss.   Now, stunned investors are suing the Company to recover some of their damages. 

Transocean provides offshore drilling for oil and gas.  Two of its rigs sat idle since mid-2023.  But, Transocean consistently assured investors that the value of its property and equipment remained stable.  Transocean also told investors it based the valuation on “fair market value.”   

In August 2024, a financial analysts asked Transocean’s CEO about the idle rigs.  The CEO said the rigs remained “strategic assets” and the Company was just looking for the right project.  That wasn’t true.  

In September 2024 the Company sold both rigs, calling them “non-strategic assets.”  The Company recorded a $630 million impairment on the sale, suggesting the rigs had been severely overvalued all along.

Shocked investors rapidly sold off their shares, causing Transocean’s stock price crashing 9% in less than a day.  Now, some of those stunned investors are taking legal action. 

Shocked investors quickly dumped their shares of AstraZeneca after Chinese authorities accused the pharmaceutical giant of insurance fraud.  The sell-off caused AstraZeneca’s stock price to plummet more than 10%, prompting some angry shareholders to file a class-action lawsuit against the Company.

In October 2024, AstraZeneca posted an announcement to its Website stating its Chinese branch president was under investigation by Chinese authorities.  A few days later, a Chinese financial news outlet reported AstraZeneca was being investigated for massive insurance fraud.  Allegedly, the Company forged prescriptions and genetic tests to ramp up benefits for some of its drugs.

In December 2024, the Financial Times published an article stating AstraZeneca executives reported revenue hits in the wake of the arrests and that some Chinese doctors were now reluctant to prescribe AstraZeneca products. 

The articles prompted shocked investors to rapidly sell off their shares.  Some of those investors are now joining the lawsuit. 

Join the Lawsuit.

Investors in Capri Holdings were left with an empty bag when the FTC blocked a proposed merger with Tapestry. Angry investors quickly sold their shares, sending Capri’s stock price into freefall. Some of those shareholders are now suing the Company to recover their losses.

In 2023, fashion company Capri received a merger offer from a rival fashion firm, Tapestry. Shareholders approved the deal. Executives from both companies assured investors they thought regulators would approve the merger.

But soon after FTC announced an anti-trust investigation, believing the proposed merged company would control too much of the handbag market. Both companies repeatedly assured investors the FTC investigation had no merit. But documents uncovered by the FTC revealed otherwise: the Companies knew their merger had major antitrust issues.

So investors were stunned in September 2024 when a federal court sided with the FTC and blocked the merger. The stock price lost 50% overnight.

Some of those shareholders now are joining a lawsuit against Capri.

Join the Lawsuit.

MGP Ingredients gave investors a headache after the distiller admitted it hadn’t been truthful about its inventory levels.   When investors learned the Company had higher inventory levels than indicated, investors quickly dumped their shares, causing MGPI’s stock price to plummet 50%.  Now, some of those investors are signing up for a class action lawsuit to recover their losses.

From 2020 to 2022, alcohol sales spiked during the Covid pandemic.  But, in  2023, when the pandemic waned, people started to drink less, leaving many distillers with excess inventory.  At that time, MGPI executives assured investors that its inventory levels were stable and sales were strong.  Yet, its executives knew better and MGPI warehouses were full of unwanted bottles.

Investors learned the truth in October 2024, when Company executives admitted soft demand for its products and higher inventory levels than previously admitted.

Analysts called the admission “breathtaking” and scolded the company for being deceptive.  Shareholders quickly sold off their stock, causing massive declines.  Now, some of those investors are pursuing legal action against the Company.

Join the Lawsuit.

Investors in Kaspi.Kz (Kaspi) were stunned after a shortseller report made shocking allegations, including violations of international economic sanctions. Stunned investors quickly dropped their shares, sending Kaspi’s stock price down 16%. Now, some of those angry investors are suing the company to recover their losses.

Kaspi is a Kazakhstan-based finance company. In 2024, it made its Initial Public Offering on the NASDAQ.  On its IPO paperwork, Kaspi assured investors it complied with international economic and trade sanctions, and other economic regulations. It also assured investors it properly disclosed any related-party transactions.

But, according to the lawsuit, Kaspi’s executives knew those assurances were far from the truth.

In September 2024, shortseller Culper Research released an explosive report alleging Kaspi knowingly dodged international economic sanctions against Russia. Kaspi also allegedly failed to disclose millions of dollars in related-party transactions with various companies.

Investors quickly sold off their stock after this news, sending Kaspi’s stock price sharply down. Now, some of those investors are signing up for the lawsuit.

Join the Lawsuit.

Investors in Marqueta were stunned when the fintech company announced its profits and revenue were far less than it led investors to expect.  When angry investors rapidly sold off their Marqueta stock, the Company’s stock price dropped over 42% in a day.  Some of those investors are now suing the Company to recover their losses.

Marqueta provides cloud-based platforms to the financial services industry.  In May and August the Company’s executives told investors to expect profit growth of over twenty percent and revenue growth between sixteen and eighteen percent.  But Marqueta’s executives should have known better, as investors would soon find out.

In November, Marqueta issued an earnings report showing profits and revenues far less than they’d led investors to expect. Marqueta’s exectuves said they “anticipated this” due to regulatory changes in banking that occurred last year.  But this explanation left investors asking why Marqueta didn’t anticipate these changes when it issued the sky-high projections just a few months earlier.

Stunned investors quickly sold off their shares, sending Marqueta’s stock price plummeting. Some of those investors are now joining the lawsuit.

Join the Lawsuit.

Applied Therapeutics is under fire after the FDA issued the pharmaceutical company a warning letter for submitting problematic data.  Shocked investors rapidly dumped their shares, causing the Company’s stock price to plummet.  Some of those investors are now suing the Company to recoup their losses.

Applied Therapeutics was investigating govorestat, a drug to treat a glucose disorder.  The Company’s executives made glowing remarks about the likelihood of FDA and European approval. 

But, those executives should have known better.

Investors learned the truth in November 2024 when the FDA issued a Complete Response Letter knocking back the drug citing “deficiencies in the application.”  Then, a few days later, the FDA sent Applied Therapeutics a stern warning letter, revealing inconsistencies in the study’s data.

Investors and analysts were stunned by the revelation, causing the stock’s price to freefall.  Now, some of those investors are joining the lawsuit.

Join the Lawsuit.

After investors learned that Cassava Sciences had lied about its clinical trials, they quickly sold off their shares in the pharmaceutical company, sending its stock price crashing 84%.  Now, some of those furious investors are suing the company to recover their losses. 

Cassava developed simufilam, a potential Alzheimer treatment.  In February 2024, Cassava announced a “clearly desirable clinical outcome” for the drug’s Phase Two clinical trials.  The good news kept coming, as in July the Company announced simufilam had entered an open-label extension study, which is typically a good sign in pharmaceutical studies.  

Things got murky for the Company in June 2024, when it announced that one of its science advisors had been indicted for defrauding the National Institutes of Health. Allegedly, that advisor lied to the NIH on simulfilam’s grant applications. Then, in October, Cassava announced the SEC levied a $40 million fine because Cassava lied about simufilam’s Phase 2b clinical trials.  The Phase 2b trials failed to meet statistical significance, but the Company never told investors about that failure.   

Investors learned the full truth about Simufilam in November, when the Company announced results of the Phase Three trials.   The drug failed all of the Phase Three trials and the Company pulled all further studies.  Investors rapidly sold off their shares after that news, sending Cassava’s stock plummeting.  Now, some of those investors are signing up for the lawsuit.  

When Five9, Inc. issued sky-high financial projections, investors’ hopes were in the clouds.  After the Company’s executives slashed those projections just months later, investors dumped their shares, sending Five9’s stock price crashing and triggered a lawsuit by shareholders seeking to recover their losses.

Five9 provides software for cloud-based business centers.  In June 2024, the Company’s executives said the Company was on track for 16% revenue growth, regardless of the economic environment.  The Company’s CEO said he was certain the Company was on track for an especially strong back half of the year. According to the lawsuit, however, Five9’s executives knew better because the Company was in the midst of a slowdown. In August, the Company released its quarterly financials and slashed its projections due to “uncertain economic conditions”  and stated that the back half of the year looked to be challenging.

Stunned investors quickly sold off their shares, sending Five9’s stock price tumbling.  Now, some of those investors are joining the lawsuit.

Join the Lawsuit.

Investors now doubt the integrity of Sun Communities, Inc. after a recent short-seller report made stunning allegations against the Company’s CEO.  Shocked investors have now filed a class action lawsuit against the company.

According to the lawsuit, in 2019, Sun Communities’ CEO took a $4 million mortgage from the parents of one of the company’s board members.  Under SEC rules, this was a “related-party transaction” that had to be reported, but the Company never filed that paperwork. The truth started to emerge in February when the Company announced that it had discovered major weaknesses in its internal controls and financial reporting. Investors learned the full scope of the problem in September after short-seller Blue Orca published a report detailing the mortgage transaction.  Blue Orca also discovered that the CEO had taken out other personal loans from Sun Communities board members, but none had been reported to the SEC. Shocked investors quickly sold off their shares.  Now, some of those investors are joining the lawsuit.

Join the Lawsuit.

Investors in Customers Bancorp were recently stunned when the Federal Reserve targeted the bank with a major enforcement action.  After learning that the Fed had slammed Customers Bancorp for failing to follow federal anti-money laundering laws, investors quickly dumped their Bancorp shares and the stock lost 15% of its value in a day.  Now, some of those investors are suing Bancorp to recover their losses.

In April 2024, Bancorp abruptly fired its Chief Financial Officer “for cause” but provided no other details.  Then, in August, investors learned the truth: Bancorp had major problems complying with anti-money laundering laws and the Bank Secrecy Act.  The Federal Reserve issued a press release announcing that it had targeted Bancorp with an enforcement action and demanded the bank implement a new risk management plan within sixty days. Investors quickly sold off Bancorp shares as the stock plummeted.  Now, some of those angry investors are signing up for the class action lawsuit. 

Join the Lawsuit.

Investors were left aching when Dentsply recently announced that its orthodontic aligner brand, Byte, had caused some patients major injuries.  Investors quickly sold their shares, dropping Dentsply’s stock price by 28% overnight.  Now, some of those sore investors have filed a class action lawsuit against Dentsply to make up for the pain caused.

In 2023, dental device manufacturer Dentsply acquired Byte, a brand of direct-to-consumer invisible aligners. Byte promised its products were doctor-directed, and Dentsply executives talked up the acquisition, especially Byte’s ability to sell new customers on clear aligners.

However, according to the lawsuit, in October 2024, the company revealed that it was in discussions with the FDA because Byte had purposefully targeted low-income consumers who should not have worn dental aligners.  These patients were treated anyway and sustained major dental injuries.

In November 2024, Dentsply released its quarterly financials, including an almost $500 million write-down on Byte’s value. Investors quickly dumped their shares.  Now, some of those investors are looking to bite back and join the class action lawsuit. 

Join the Lawsuit.

Celsius Holdings, Inc. gave investors the wrong sort of buzz after executives revealed sales were down over $100 million.  Stunned investors emptied out their shares, causing Celsius’ stock price to plummet almost 12%.  Angry investors are now suing the company to recover their losses.

Celsius, a popular energy drink brand, formed a distribution alliance with Pepsi 2022.  The company then reported record sales in 2023, causing its stock price to skyrocket.  Celsius’ executives then cashed out, banking well over $1 billion, but didn’t tell investors that the record sales were because Pepsi had hoarded over two years’ worth of Celsius in warehouses.  Thus, 2023 sales weren’t likely to repeat any time soon.

The truth emerged in September 2024, when a Celsius executive spoke at an industry conference.  He said sales were down almost $100 million because Pepsi was using its massive stockpile to stock shelves instead of ordering new cans.

Stunned investors quickly dumped their shares, causing Celsius’ stock price to crash.  Some of those investors are now signing up for the lawsuit. 

Join the Lawsuit.

When entertainment giant Warner Bros. Discovery, Inc. recently announced that it had taken a $10 billion, investors weren’t amused.  Shareholders quickly dumped their stock, causing Warner Bros.' stock price to tumble 9% overnight.  Some of those shareholders have now filed a lawsuit against the company. 

In February, Warner Bros. announced that it was renegotiating its contract with the NBA, which was a centerpiece of the company’s entertainment line-up, but those negotiations ran long. In August, the company issued its financial results, and investors were shocked when the company announced a $10 billion write-down for the value of the company’s brands and networks. 

According to the lawsuit, Warner Bros.' executives should have known that lengthy negotiations would hurt the brand’s value.  Plaintiff also claims that Warner Bros. executives should have known the brand was overvalued in the first place, which would result in the hefty write-down.  Nonetheless, Warner Bros. executives let investors buy WBD stock at an inflated price.

Now, some of those angry investors are joining the lawsuit.

Join the Lawsuit.

Investors in Zeta Global Holdings quickly dumped their shares after a recent short seller report made shocking allegations against the digital marketing company.  After Zeta’s stock price plummeted 37% overnight, some of Zeta’s investors filed a class action lawsuit to recover their losses.

Zeta is a digital marketing company that holds data about over 240 million Americans.  Zeta says those people voluntarily disclosed their information, but in November Culper Research published a report that raised serious questions about Zeta’s data set.  The Culper report said Zeta tricked consumers into disclosing personal information by setting up bogus web sites like fake job boards.  Culper also claimed Zeta used underhanded tactics to inflate its revenue by over 50%.

Shocked investors quickly sold off their shares after the Culper Report was released.  Now,  some of those investors are signing up for the lawsuit.

Join the Lawsuit.

Aehr Test Systems, Inc. short-circuited investors’ hopes when the semiconductor Company recently slashed its financial projections by millions.  Upset investors quickly sold off their Aehr shares, and Aehr’s stock price fell over 22%.  Now, shareholders have filed a class action lawsuit against the Company.

In late 2023, Aehr issued its 2024 fiscal guidance.  Aehr executives expected at least $100 million in revenue.  In January 2024, Aehr revised projections down to $75-85 million, but the Company’s CEO assured investors there was “no way” the Company would miss this new goal. He was wrong., and in March, the Company stunned investors when it reported dismal quarterly income and slashed its revenue target yet again. After the March revision, investors quickly sold off Aehr’s stock, sending the stock price plummeting.

Join the Lawsuit.

Dutch semiconductor manufacturer ASML Holding N.V. missed the mark when it assured investors that it was on track for record sales by 2025.  So, when investors learned sales had short-circuited and ASML’s projections were off-track, they quickly sold off their stock, causing ASML’s stock price to plummet.  Now, some of those shareholders have filed a class-action lawsuit against the company.

In early 2024, ASML announced record sales, and company executives told investors they expected 30 to 40 billion Euros in sales in 2025.  According to the recent lawsuit, however, executives should have known these projections were far-fetched because the Dutch government imposed strict export regulations on China in 2023. Much of ASML’s sales depended on China, so ASML’s executives should have known hitting their sales goal was almost impossible. In October 2024, investors learned the truth when ASML announced a 53% decline in quarterly bookings.  The Company also slashed its 2025 sales target. 

Investors quickly sold off their ASML stock.  Now, some of those investors are joining the class action lawsuit to recover their losses.

Join the Lawsuit.

In July, the NASDAQ delisted Chinese AI company Xiao-I because it had become a junk stock. Now, angry shareholders are suing the tech company to recover some of their lost investment.

When Xiao-I launched its initial public offering in 2023, its executives should have known the company had problems. It wasn’t in compliance with Chinese foreign investment laws, it didn’t meet NASDAQ accounting requirements, and its AI model needed a lot more work. Xiao-I didn’t tell investors about any of those issues, and investors were outraged when they learned the truth the hard way- when NASDAQ took the shares off the market for failing to meet even minimum quality requirements.

Some of those shareholders are now signing up for the class-action lawsuit.

Join the Lawsuit.

After dismal holiday sales, toy manufacturer Hasbro left investors holding a lump of coal. When investors quickly dumped their shares, Hasbro’s stock plummeted 11% overnight. Some of those angry shareholders have now filed a class action lawsuit against Hasbro hoping to recover their lost investment.

During the early stages of the Covid pandemic, Hasbro loaded up on inventory due to the increased demand for at-home activities. Unfortunately, the company over-bought and was left with warehouses full of unwanted games and toys. Hasbro executives assured investors that these extra toys were actually in anticipation for the 2022 holiday season, but in reality, demand for Hasbro’s products had diminished.

Investors learned the truth in October 2023: the toy giant failed to sell the excess inventory, which remained in warehouses. Executives announced a one-time, $55 million expenditure to aggressively market and apply heavy discounts to the merchandise.

Stunned investors quickly sold off their Hasbro shares, cause the stock’s price to freefall. Now, some of those shareholders are signing up for the class action lawsuit.

Join the Lawsuit.

Investors were shocked when banking giant Toronto-Dominion Bank recently announced a settlement with the U.S. government over failures in the bank’s anti-money laundering systems.  The settlement terms not only required Toronto-Dominion to pay a massive fine, but also to restructure its books.  Stunned investors dumped their shares, causing Toronto-Dominion’s share price to plummet 10% in just two days.  Now angry shareholders have filed a class action lawsuit against the bank, adding to the Company’s legal woes.  

According to that lawsuit, throughout much of 2024, Toronto-Dominion’s executives issued remarks reassuring investors about the Company’s ability to comply with U.S. anti-money laundering laws.  Even after the bank became the target of a U.S. government probe, executives downplayed the likelihood of a major fine and told investors that the company would continue to do business as usual.  In reality, those executives knew the U.S. Government was likely to hit Toronto-Dominion with massive fines and force the bank to restructure.

Investors learned the truth in October when Toronto-Dominion issued a press release announcing its settlement with the U.S. government.  The bank paid over three billion dollars in fines, and the government capped Toronto-Dominion’s total assets, forcing the bank to restructure its balance sheet and reduce its total assets by 10%.  

When investors discovered this settlement, they quickly offloaded their shares.  Some of those upset investors are now signing up for the class action lawsuit in hopes of recovering their lost investment.

Join the Lawsuit.

Chipotle’s feeling the heat after media reports criticized the Mexican food chain’s skimpy portion sizes.  When hungry customers’ allegations caused the chain’s bottom line to plummet, investors responded by tossing out their shares.  Some of those shareholders have now filed a class action lawsuit against the company.

In mid-2024, Fox Business and other media outlets reported that Chipotle’s portion sizes were inconsistent or meager.  The chain denied the allegations while also implementing efforts to ensure their meals had more heft. 

Investors were stunned when the Company released its earnings report in October 2024.  After implementing consistent portion sizes, Chipotle’s costs skyrocketed, causing revenues to go sour.  When investors discovered the truth – that Chipotle couldn’t be profitable while also filling up customers’ plates – they dumped their shares, causing the stock price to plummet. 

Shareholders are now joining the class action lawsuit. 

Join the Lawsuit.

Investors have chilly feelings about Iris Energy Limited after the bitcoin mining operation recently lost big. While Iris sold investors on hopes of a high-power computing facility, in reality, investors got left in the dark when that computing facility had inadequate facilities to get the job done. Aggrieved investors pulled the plug on Iris stock, which dropped 15% in one day. Some of those investors recently filed a class action lawsuit in hopes of recovering their losses.

According to the lawsuit, in 2023 Iris issued a press release announcing it was opening new, high-powered data processing centers, shifting its focus from cryptocurrency mining. Public statements also emphasized these centers’ cooling efficiency, which is important because high-powered computing uses a great deal of energy. In reality, Iris’ executives knew this new site was ill-equipped for use as a data center and that the cooling systems were sub-par. Despite that knowledge, Iris’ executives fraudulently allowed these over-the-top promises to be published anyhow.

The truth came to light when Culper Research published a disturbing report revealing that Iris had severely oversold its abilities, particularly at its Texas site in Childress County. After this report came out, shocked investors dumped their shares, causing Iris’ price to plummet.

Some of those angry shareholders are now joining the class-action lawsuit.

Join the Lawsuit.

WM Technologies gave investors a high when the Company published overly rosy numbers on the Company’s financial reports.  But those figures went up in smoke after the SEC announced an investigation of the cannabis company’s fraudulent financials.  Angry investors quickly dumped their shares, causing the stock to tumble.  Those investors have now filed a class-action lawsuit against the Company in hopes of recovering some of their “green.”

WM is an online cannabis marketplace.  In its quarterly SEC reports, WM includes metrics for its monthly active users and paying clients.   Between 2021 and 2022, the Company’s quarterly reports showed it regularly increased those key figures.  But, according to the lawsuit, WM’s executives should have known those numbers were fraudulent and the result of misleading and deceptive accounting practices. 

The truth came to light in 2022 when the Company filed an SEC report revealing that an internal whistleblower had called out WM’s bogus method for counting active users and clients.  Then, in 2024 the SEC filed litigation against the company and its executives, based in part on those allegations.

Investors quickly sold off their shares after learning this news, causing WM’s share price to plummet.  Some of those investors are now signing up for the class action lawsuit.

Join the Lawsuit.

Delivery giant UPS dropped the package and shattered investors’ hopes when it missed its own financial projections.  While the Company suggested it was on track for improved revenues and profitability in the second half of 2024, actual earnings proved lackluster.   UPS’s stock price quickly plummeted, prompting some shareholders to file a class action lawsuit to recover their losses.

In early 2024, UPS issued a press release announcing its financial results.  The Company said that while it anticipated challenges and flat growth early in the year, it expected 10% margins by year’s end.   In reality, Company executives used faulty assumptions and bad data when issuing these overly ambitious and bogus projections.

Investors learned the truth in July when UPS issued a press release announcing its quarterly financial results.  The report revealed that earnings had crashed, which resulted in UPS slashing its previously ambitious financial targets.    Investors quickly dumped their shares after this news, causing UPS’s share price to tumble.  Upset investors affected by this nosedive are now signing up for the lawsuit. 

Join the Lawsuit.

Foot and ankle orthopedic manufacturer Paragon 28 tripped up when it issued financial statements that seriously misled investors about  costs and inventory levels.  When investors learned the truth about these accounting practices, Paragon shares fell 20% overnight.  Some shareholders have now filed a class-action lawsuit against the Company to recoup their losses. 

Paragon repeatedly released quarterly financial reports detailing the Company’s assets and liabilities.   According to that lawsuit, on each of those reports, Paragon executives affirmed that the Company maintained effective control over financial reporting.   In reality, investors say, Paragon’s executives knew they lacked control over the Company and that as a result, there were major problems in the Company’s financial reports, including discrepancies of millions of dollars in costs and inventory.

The truth came out in 2024 when the Company filed a report with the SEC stating that investors should not rely on the Company’s previous financial reports because they were fraudulent.  Shareholders are now signing up for the lawsuit to recover some of their losses.

Investors in artificial intelligence company iLearning Engines were shocked to discover that the company’s financial statements were artificial too.  A recent Hindenburg report revealed that most of company’s revenue was largely fake, making the company’s financial statements unreliable.  Following this news, investors pulled the plug on the stock, causing stock price to plummet 35% in one day.  Angry shareholders recently filed a class-action lawsuit hoping to recover some of their losses.

According to that lawsuit, iLearning Engines frequently published overwhelmingly positive statements about the company’s revenue and expenses, attributing much of this success to their “Technology Partner.”  These reports failed to disclose this technology partner was a related party that iLearning Engines used to fake its revenue and expenses.  In reality, iLearning’s revenue was 99% less than what was reported on its financial statements, with the vast majority of its revenue being fraudulently claimed through this related entity. Investors allege that executives failed to exercise proper control over iLearning’s financials, which allowed for this fraud to occur.

Investors learned the truth in August 2024, when Hindenburg Research published “iLearning Engines: An Artificial Intelligence SPAC with Artificial Partners and Artificial Revenue” and quickly sold off iLearning stock.  Affected investors are now signing up for the class action lawsuit.

Join the Lawsuit.

Share prices for satellite manufacturer Terran Orbital crash-landed after its recent acquisition by Lockeed Martin. Investors allege that while Lockheed originally offered a sky-high price for Terran shares, when the final deal price was in the dirt. Angry shareholders are now suing Terran to recoup their losses.

According to the class action lawsuit, in 2023, Terran won a major, multi-billion dollar contract. Company executives assured investors the Terran had adequate cash reserves and resources to fund the contract. In reality, company executives knew Terran was cash-strapped, unable to fulfill the order, and thus unlikely to profit on this contract.

In April 2024, defense industry giant Lockheed Martin offered to buy out Terran at one dollar per share, but soon withdrew the offer. Terran later announced that it was short on cash and removed the major contract from its backlog, slashing the Company’s outstanding contracts by almost 90%.

Following this disappointing news, Terran announced that Lockheed had renewed its offer – this time at forty cents per share. The next day, Terran announced its final deal with Lockheed, which valued Terran at just twenty-five cents per share. Investors reacted negatively and Terran shares crashed 39% overnight. Some investors are now signing up for the class-action lawsuit in hopes of recouping their losses.

Join the Lawsuit.

Investors are barking mad at Elanco Animal Health after it botched the rollout of two new canine drugs, Zenrelia and Credelia Quattro. Elanco repeatedly pushed back the rollout date for both drugs, and Zenrelia proved less safe than initially thought. After investors learned the truth, Elanco stock plummeted. Angry investors recently filed a class-action lawsuit against the company, hoping to recover some of their losses. According to the lawsuit, Elanco published ambitious statements about the release date for Zenrelia and Credelia Quattro, two prescription drugs for dogs. The pharmaceuticals were meant to be released in the first half of 2024. However, after being backed up several times, the release date was delayed the fourth quarter of 2024. Further, the Company revealed that Zenrelia would be released with a boxed safety warning because the drug showed safety problems, and executives expected this warning to slow the drug’s profitability. Investors were shocked when they about learned of these problems in a June 2024 press release. Investors quickly sold off their shares, causing Elanco stock to drop more than 20% overnight. Shareholders are now joining the class action lawsuit in hopes of recovering some of their lost money.

Join the Lawsuit.

Dating app Bumble tries to help its users find love, but investors dumped the stock, which plummeted 29% in August. This messy break-up followed an announcement that Bumble had fumbled the roll-out of its Premium Plus product and a report of bleak financial results. Those investors have now filed a lawsuit against Bumble. According to the lawsuit, in late 2023, Bumble executives announced the app’s higher-priced Premium Plus subscription feature, suggesting that it would be a strong selling point for Bumble users. Bumble’s executives also indicated that they expected increased revenue in 2024, driven in part by Premium Plus. Investors and analysts learned the truth when Bumble later issued a press release announcing disappointing financial results and that users weren’t attracted to Premium Plus. The Company went on to post losses for three quarters in a row, until disgusted investors finally bailed, prompting the August sell-off. Shocked investors are now signing up for the class action lawsuit in hopes of recovering some of their losses.

Join the Lawsuit.

Domino's Pizza burned investors when it recently botched its long-term financial guidance. As a result, investors dumped the stock, causing share price to plummet almost 14% overnight. Investors singed by the drop have now filed a class action to recoup some of their lost “dough.” According to that lawsuit, in 2023, Domino's executives issued guidance stating that the pizza giant expected to open 1100 stores globally by 2028. They also suggested that the Company was on track for sales and income growth. Executives failed to tell investors and analysts that, at the time of that guidance, Domino's was already experiencing major challenges with respect to store closings and was likely to miss its previously issued financial guidance. Investors got served a piping hot slice of the truth in 2024 when Domino's issued a press release stating that the Company had “suspended” its goal of eleven hundred store openings. Domino's also announced some store closures internationally. Analysts and investors reacted negatively to that news, and aggrieved investors are now signing up for the class action lawsuit.

Join the Lawsuit.

Natural gas company New Fortress Energy is facing a class action lawsuit filed by investors who claim the Company delivered nothing but a well of empty promises. In early 2024, New Fortress executives issued a gushing annual fiscal outlook which suggested the Company would double key financial metrics and close out key projects.  When investors learned these projections were just hot air, New Fortress stock plummeted 23% overnight, prompting investors to file suit. 

According to that lawsuit, in February 2024, New Fortress executives issued a press release describing the Company’s financial position.  In that release, the Company suggested it was nearing completion of key projections in Brazil and Puerto Rico and was close to winning a major project in Mexico.  The Company also suggested it was on track to double key financial metrics such as revenue in 2024, but investors allege that executives made these statements while concealing negative facts about these projects’ viability and timetables.

The truth emerged later that year, when New Fortress issued a press release revealing that earnings had slowed to a trickle and slashed its guidance for the second half of the year.  In particular, it announced delays for the Brazil, Puerto Rico, and Mexico projects, all of which would harmed company profits.  

Shares cratered overnight following this news, and shareholders who lost money on that drop are now joining the lawsuit.

Join the Lawsuit.

STMicroelectronics is a global semiconductor company, so management should know the importance of precision and getting things right.  But when STM recently botched the job on its financial outlook and got the numbers all wrong, its share price lost 15% just in one day.  Shareholders are now suing the company in an attempt to recoup their losses. 

In late 2023, STM executives provided investors and analysts with a glowing financial update.  Executives played up the Company’s strong margins and revenues, supposedly driven by strong automotive and communications segments.   In reality, Company executives knew demand for STM products was declining and causing revenues and margins to shrink too.

Investors and analysts were stunned when, in April 2024, STM executives revealed the truth: shaky automotive and communications segments caused STM’s margins and revenues to shrink, and overall sales declined almost 20% from the prior year.

After this revelation, investors lost confidence and began dumping STM stock and signing up for the class action lawsuit that was later filed.

Join the Lawsuit.

Starbucks got the order wrong when it revamped its rewards program and global success plan. While the Company told investors these strategies were piping hot, investors were left in the cold when these plans proved to be stale. Investors say executives made baseless claims about the Company’s financial outlook using bad data and unfounded optimism. These investors have filed a class action lawsuit.

According to aggrieved investors, in late 2023, Starbucks’ executives gave investors a positive outlook for the company’s Reinvention Strategy, which included revising the coffee chain’s rewards programs, opening more stores internationally, and a positive financial outlook for U.S. stores. The buzz was short-lived. Just six months later, the Company issued a press release showing dismal financial results and declining global sales.

After learning the truth, investors quickly dumped Starbucks shares, causing the stock to lose 15% of its value overnight. Shareholders are now pursuing a class-action lawsuit to recoup some of their losses.

Join the Lawsuit.

A company without a leadership team loses its nerve, and when orthopedics manufacturer Orthofix botched its merger with SeaSpine, the Company lost its nerve, most of its board, and 30% of its share price.

When Orthofix announced its merger with SeaSpine, another orthopedics company, Orthofix gave investors an excellent prognosis, suggesting there was a great culture fit between the two companies. Instead, less than a year after the deal, Orthofix had to remove the new executives due to offensive and problematic conduct. Shockingly, Orthofix did not announce replacement officers, leaving an open wound in the Company’s leadership team.

Although Orthofix said these firings wouldn’t affect financial results, investors and analysts were horrified by the executives’ crass conduct and the company’s lack of transparency. Orthofix’s stock price plummeted, and investors were quick to file a lawsuit. Affected investors are now signing up for that class action in the hopes of recouping some of their losses.

Join the Lawsuit.

After shares in Super Micro Computer, Inc. fell 21% overnight in August, 2024, shareholders waved the red flag and filed a class action lawsuit against the company.

SMCI makes and develops various computing technologies. For years, the Company consistently issued glowing financial projections to investors. Those statements short-circuited when, in August 2024, a short seller report alerted the public that SMCI was engaged in self-dealing, had various accounting irregularities in its books, and its patents might have technical problems. Additionally, investors learned SMCI might be running afoul of U.S. export laws, putting the Company at risk of government sanctions.

Investors and analysts expressed shock at the short seller report findings, and investors pulled the plug on SMCI shares, causing many shareholders to suffer financial losses. These shareholders are now joining the recently filed class action lawsuit.

Join the Lawsuit.

Spire Global, Inc. shareholders recently filed a lawsuit against the satellite data and analytics company when Spire’s sky-high projections ended in a financial crash-landing. After Spire’s executives revealed that the Company was using dodgy data and analytics to make financial projections, Spire’s shares plummeted 33% overnight, causing heavy losses for shareholders.

According to the recently filed lawsuit, throughout much of 2024, Spire’s executives communicated to investors and analysts that the Company’s revenue and profits were improving. Executives also told investors they expected continued growth throughout 2024 from a number of contracts and projects Spire had won.

In August 2024, investors learned the truth when the Company issued a press release updating its financial projections. Investors and analysts were horrified to learn that the over-the-moon projections were, in reality, due to unusual accounting practices and other mismanagement. Investors quickly dumped the stock, causing its price to crash.

Those shareholders are now suing Spire in hopes of recouping some of their losses.

Join the Lawsuit.

Verve Therapeutics, Inc. broke investors’ hearts when its clinical trials of a novel drug flatlined.  Now investors are returning the heartache, filing a class action lawsuit alleging that Verve executives knowingly misrepresented various aspects of the clinical trials.

Verve Therapeutics is a genetic medicine company specializing in cardiovascular care.  In 2022, Verve announced the “Heart 1” clinical trials for VERVE-101, a novel drug designed to reduce LDL cholesterol.  The Company also touted the superiority of its propriety delivery system for VERVE-101.

According to the lawsuit, when Company executives described the Heart-1 study to investors and analysts, they didn’t announce the low threshold for calling off the whole study.  Investors claim that executives had long-standing, undisclosed reservations about the delivery system’s effectiveness and always knew they’d pull the plug on the program after any single adverse event.

In 2024, Investors learned the truth when the Company released a press release announcing that Verve had halted the Heart-1 trial due to a single adverse event.  Shocked investors dumped Verve stock, causing it to lose 35% of its value overnight.  Aggrieved investors are now joining the class-action lawsuit hoping to recoup some of their losses.

Join the Lawsuit.

If you enjoy receiving unsolicited marketing calls and emails, you can thank your friends at ZoomInfo Technologies. This software and data company’s principal product is a data platform that provides customer contact and business information to sales and marketing teams. It may annoy consumers, but it’s good business- or it at least it was until ZoomInfo stocked declined by ninety percent. Now it’s not just consumers who are angry, it’s shareholders too, and they’ve filed a lawsuit.

The lawsuit claims that the positive effect COVID-19 had on ZoomInfo’s growth was short lived, and large portions of ZoomInfo’s customer base were trying to lower their usage or abandon the product altogether. ZoomInfo used a bevy of unethical tactics to retain customers including manipulative and coercive auto-renew policies and threats of litigation, and these tactics had materially damaged the Company’s customer relationships, client franchise, and competitive advantages.

Find out if you're included by clicking here.

DexCom, Inc. develops, manufactures, and distributes continuous glucose monitoring systems for diabetes management. In the United States, about eleven percent of the population has diabetes, so DexCom seemed like a solid investment to many. That is, until July 2024, when DexCom announced disappointing financial results, and its stock price plummeted over 40 percent. Now shareholders claim that their losses aren’t just a disappointment, they’re the result of fraud.

Join the lawsuit.

Advances in biotechnology can have amazing results for patients, but bringing a drug to market can be a risky business for companies and investors. And the risks don’t end once a therapy is on the market, as investors in Ardelyx, Inc. learned when they lost over thirty percent of their investments. These shareholders claim that their losses aren’t the result of risky investing but of fraud by Ardelyx. Any shareholder who incurred a loss due to Ardelyx’s alleged misconduct can join the recently-filed lawsuit.